Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission
about
CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected IndividualsComparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1)Dual Function of Ccr5 during Langat Virus Encephalitis: Reduction in Neutrophil-Mediated Central Nervous System Inflammation and Increase in T Cell-Mediated Viral ClearanceEstimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusionCCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug usersFunctional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility.CCR5 haplotypes and mother-to-child HIV transmission in Malawi.Regulation of CCR5 expression in human placenta: insights from a study of mother-to-child transmission of HIV in Malawi.Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cellsCCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis.CC chemokine receptor 5 gene polymorphisms in beryllium disease.Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.MicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell countsConcordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression ratesGenetic and Immunological Factors Involved in Natural Resistance to HIV-1 Infection.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successOutcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals.CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men.Host factors influencing susceptibility to HIV infection and AIDS progression.Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptorOpiate drug use and the pathophysiology of neuroAIDS.CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea.Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.Global human genetics of HIV-1 infection and China.CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effectsReduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic ApproachesMendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia.Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners.Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals.Genetics and the general physician: insights, applications and future challenges.Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs.CCR5Delta32 protein expression and stability are critical for resistance to human immunodeficiency virus type 1 in vivoElite control of HIV infection: implications for vaccine design
P2860
Q19028101-5F3AB94D-C82D-4B07-8AD9-03E8AF5E749AQ21560946-33B8F365-F151-47F5-BBF9-A571CEE5AF7CQ26700108-B5351ACE-B8C4-48F2-B6DB-437DE16C88CBQ28478341-A8ED912C-8229-483E-8C12-F6EC486F9711Q28534869-23C3A9E6-C56C-4F3D-A927-20622989557EQ30376421-BC58D856-DF0B-4AAE-B1C3-E61AA1D9BB9BQ33296998-C92CBCB2-9104-4DD5-BABC-F48B06121387Q33532625-3ECDF5FA-2484-4AF0-8838-D4874031773AQ33613769-EE697CC0-0E8A-4994-BC49-65807ACF6026Q33669282-B463B403-9341-4463-ABBF-448BE81AC5E1Q34092814-14823F6C-480D-429D-8849-B020A4FD6025Q34230435-F2834E38-0C98-45F8-9DD6-19B0EB089DBFQ34574397-BEC6492A-3FBF-4049-9D9E-775D5F497117Q34747583-1F0A1C5C-EBE1-40D9-93E2-29DE12EA3C37Q34763459-89174082-853D-4F08-825B-3810557F5F63Q35030053-A4C329BB-D6FC-4ADF-9BDA-94B764FA1191Q35043700-469C6A11-9647-412A-98AC-C8CB9A646332Q35092851-E0D9472C-0EEE-4A20-87AC-E92DD2734DC2Q35121515-A233E3EE-3A3C-4B97-BEAC-95F1747ADC1DQ35995936-DE0BC012-61A8-4492-B7D1-A2C281CBA73CQ36008317-64444488-BA48-4997-95E8-45E2EF5484E8Q36201412-8D8C4D55-8D63-4B71-9B74-0BCC8FCB3359Q36279685-80AFEFE3-163D-46E7-BE81-DD1B08B2866AQ36315197-060002EA-049C-4A18-BAE8-D729896769D0Q36342033-79FC67D8-14A8-4ABA-BDF9-C2BA2A3F41D0Q36483857-B1E09B2E-47AF-448C-8EC7-B10C44733F1BQ37068522-8CAF3A4C-CDD5-4919-9AE0-B6C2946B9C6FQ37073520-E381C418-8AFF-4062-80B2-B3F999BED50BQ37185404-709CA67E-FED3-409F-BF96-DF8A16430A8EQ37252004-A8697F23-2F5D-4E54-9753-F1929E73B274Q37295610-7338D487-76BD-4192-82D2-6D56D9864148Q37359177-1B6D6B04-33B6-4734-B5E3-5E3E38D82752Q37365402-FB18610E-FF6C-4DB7-B2ED-F323CFECEF8FQ37393689-F057EEFA-6F20-46D1-8694-B4D28A9415A0Q37396981-D45B2B0E-2612-4E39-AB3E-9D95A50A2742Q40179209-4DB772D0-5F93-4329-8A95-868615CBB803Q41860559-6CEF70F4-2685-46AA-9AB1-20420D252F31Q56994404-EC21EAC7-B8FB-47F3-8C2E-33156EF39652
P2860
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@ast
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@en
type
label
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@ast
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@en
prefLabel
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@ast
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@en
P2093
P2860
P50
P1433
P1476
Combined effect of CCR5-Delta3 ...... ency virus type 1 transmission
@en
P2093
Benjamin Greene
Devon Livingston-Rosanoff
Emily Speelmon
Polachai Sakchalathorn
Sean Wilson
Yon Hwangbo
P2860
P304
11677-11684
P356
10.1128/JVI.79.18.11677-11684.2005
P407
P577
2005-09-01T00:00:00Z